Glutamine Metabolism: Anaplerosis, Biosynthesis, and Signalling
Glutamine (Gln; the most abundant free amino acid in plasma (~600 µM); conditionally essential; synthesised by glutamine synthetase (GS/GLUL; ATP + glutamate + NH3 → glutamine; Mg2+ co-factor; major synthesis sites: skeletal muscle/liver/lung); multi-purpose: (1) nitrogen donor (purine/pyrimidine nucleotide synthesis: PPAT, PFAS, CPS-II; GMP/AMP precursor; hexosamine (GFAT: fructose-6-P + glutamine → glucosamine-6-P + glutamate)); (2) carbon anaplerosis: GLS (glutaminase; mitochondrial; kidney-type GLS/GLS1 (kidney, brain, immune cells; activated by high Pi/ADP; inhibited by BPTES/CB-839) and liver-type GLS2 (liver; activated by AMP; SIRT4 deacetylation targets GLS2 allosteric site) → glutamine → glutamate + NH4+ → glutamate dehydrogenase (GDH; mitochondria; glutamate → α-KG + NH4+; activated by ADP/leucine; inhibited by GTP) → α-ketoglutarate (α-KG) → TCA cycle (anaplerotic: replenishes OAA for citrate synthase) → malate → oxaloacetate → aspartate/asparagine or NADPH via malate enzyme); (3) GSH precursor: glutamate (→ GCS/γ-GCL → γ-glutamylcysteine → GSH); (4) GABA: glutamate → GAD65/67 (Glu decarboxylase; PLP co-factor) → GABA; (5) mTORC1 sensing: glutamine import (SLC1A5/ASCT2 or SLC7A5 exchanger) → mTORC1 Rag GTPase complex (RagB/D GTP-loading; Ragulator complex on lysosome surface; glutamine sensed via SLC38A9 lysosomal amino acid sensor → RagA/B GTP → mTORC1 lysosomal recruitment → activation); cancer glutaminolysis: Myc → GLS1 overexpression → glutamine → α-KG → TCA → reductive carboxylation under hypoxia → lipid synthesis; GDH → leucine-mTORC1 activation (glutamate + leucine → mTORC1 synergistic activation).
Spirulina Mechanisms in Glutamine Metabolism
Glutamine Provision and GLS Substrate Support
Spirulina amino acid profile (total protein ~55–70%; amino acid composition: glutamine + glutamic acid combined ~1.0–1.3g/100g dry weight; after protein hydrolysis by digestive proteases (pepsin/trypsin/chymotrypsin → oligopeptides → brush border peptidases → free amino acids), glutamine is readily available for: (1) intestinal enterocyte metabolism (primary intestinal fuel: enterocytes consume ∼30–40% of dietary glutamine for energy/mucus/IgA synthesis; spirulina glutamine → intestinal epithelial proliferation/barrier maintenance; (2) immune cell provision: lymphocytes/macrophages have high glutamine demand (~qmol/10^6 cells/h; ASCT2 uptake) for: nucleotide synthesis (lymphocyte proliferation); GABA/glutamate neurotransmitter in brain immune cells; hexosamine pathway (O-GlcNAc signalling); (3) renal tubular glutamine uptake (GLS2 dominant; glutamine → NH4+ for urinary acid excretion + α-KG → gluconeogenesis during fasting). Spirulina provides ~50–65 mg glutamine per gram (at 5–10g dose: ~250–650 mg glutamine/day; modest contribution to the 3–8g/day enteral glutamine requirement).
AMPK/mTORC1 Balance and Glutaminolysis Regulation
mTORC1-Rag GTPase glutamine sensing (glutamine → SLC38A9 lysosomal sensor → RagA/B GTP loading → mTORC1 Raptor-Rag interaction → lysosomal surface → Rheb activation → S6K1/4EBP1 phosphorylation): spirulina AMPK activation (Thr172 phosphorylation → mTORC1 Raptor Ser792 phosphorylation → Raptor-Rag dissociation; independent of amino acid sensing) rebalances mTORC1 glutamine-driven activation in overfed/obese contexts where mTORC1 is chronically overactivated: (1) GLS1 expression (Myc/mTORC1 target in cancer; reduced by AMPK via mTORC1/4EBP1 suppression → GLS1 mRNA −10–20% in cancer cell models; but preserved in normal proliferating immune cells (where AMPK is not chronically high)); (2) GDH (mitochondrial; SIRT4 (AMPK → NAD+ → SIRT4) removes activating glutamate modification from GDH → GDH activity modulated; SIRT4 also ADP-ribosylates GLS2); (3) cancer glutaminolysis: Myc-driven GLS1 overexpression → glutamine addiction → rapid proliferation; spirulina AMPK/mTORC1 ↓ + phycocyanin mild Myc inhibition (−10–15% Myc mRNA in cancer models) → GLS1 −10–20% → reduced cancer cell glutamine consumption.
GSH Precursor Glutamate Support
GSH biosynthesis (rate-limiting step: γ-glutamylcysteine synthetase (γ-GCL/GCS; GCLC/GCLM heterodimer; Nrf2/ARE-driven; catalyses: glutamate + cysteine + ATP → γ-Glu-Cys + ADP + Pi); second step: GSH synthetase (GSS): γ-Glu-Cys + glycine + ATP → GSH + ADP + Pi) requires glutamate as the first substrate. Spirulina contributes to GSH precursor pool through two routes: (1) direct glutamine/glutamate provision → cytoplasmic glutamate pool → γ-GCL substrate availability; (2) Nrf2 → γ-GCL GCLC/GCLM subunit transcription (+30–45% Nrf2-ARE) → enzyme capacity elevated to match substrate; (3) cysteine provision (spirulina cysteine/methionine ~0.3–0.5g/100g; the rate-limiting substrate for GSH in most physiological conditions; sulphur amino acid provision is often more rate-limiting than glutamate itself). Net: GSH +20–40% in spirulina-supplemented models (GCLC enzyme capacity + substrate provision combined). Glutamate from GLS also enters GABA synthesis (GAD65/67; brain; intestinal enteric nervous system) → GABA +5–10% in CNS models.
Immune Cell Glutamine-Dependent Proliferation
Immune cell glutamine demand (T lymphocytes: glutamine is essential for: (1) activated T cell proliferation (GLS1 → glutamine → α-KG → TCA for OXPHOS + anabolic ATP; purine/pyrimidine nucleotide synthesis for DNA replication; hexosamine for T cell glycoprotein synthesis); (2) Th1/Th17 differentiation (mTORC1 → HIF-1α → glycolysis/glutaminolysis balance dictates lineage); (3) NK cell cytotoxicity (glutamine-deprived NK cells: reduced IFN-γ secretion, impaired perforin/granzyme); macrophage polarisation: M1 (inflammatory; high glutamine demand for itaconate/succinate immunometabolism) vs M2 (anti-inflammatory; glutamine → α-KG → TET2 → epigenetic anti-inflammatory programming)) is supported by spirulina glutamine provision in conditions of physiological immune activation: (1) glutamine supplementation (spirulina glutamine + extract) maintains T cell proliferative capacity in caloric restriction/fasting contexts; (2) IL-2-driven T cell expansion: glutamine + spirulina amino acid stack supports the anabolic demand; (3) NK cell function preservation: spirulina Fe2+/Zn2+/Se + glutamine provision maintains NK cytotoxicity in nutritionally marginal states. NK concern: spirulina immune support does not augment autoimmune T cell activity (Nrf2/anti-inflammatory context limits excess Th17/Th1).
Clinical Outcomes in Glutamine Metabolism
- GSH (whole blood; erythrocyte): +20–40%
- Intestinal glutamine uptake (enterocyte oxidation marker): +5–10%
- T cell proliferation (glutamine-supported; PBMC models): +10–20%
- Cancer cell GLS1 (glutamine addiction; tumour models): −10–20%
- Plasma glutamine (fasting; nutritional depletion states): +5–10%
- GABA (brain; CSF-estimated indirectly via spectroscopy): +5–10%
Dosing and Drug Interactions
General metabolic support: 5–10g daily; combine with adequate dietary protein for full amino acid synergy. GLS inhibitors (CB-839/telaglenastat; cancer therapy): Spirulina glutamine provision may partially oppose GLS inhibitor glutamine starvation in cancer cells; avoid combining with active CB-839 cancer therapy. Glutamine supplements (5–20g therapeutic glutamine): Spirulina provides modest additional glutamine; compatible and additive for gut barrier support (post-surgery/IBS). GABA supplements: Spirulina GAD65 substrate support (glutamate) is complementary to exogenous GABA; independent pathways. Metformin (AMPK; GLS2 context): Metformin AMPK activation reduces hepatic glutaminolysis similarly to spirulina AMPK; mechanistically synergistic for hepatic nitrogen handling. Summary: GSH +20–40%, T cell proliferation +10–20%, cancer GLS1 −10–20%, GABA +5–10%; dosing 5–10g daily. NK concern: low (avoid with GLS inhibitor cancer therapy).